These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32651552)

  • 1. Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England.
    Flaum N; Morgan RD; Burghel GJ; Bulman M; Clamp AR; Hasan J; Mitchell CL; Badea D; Moon S; Hogg M; Hadjiyiannakis D; Clancy T; Schlecht H; Woodward ER; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Lalloo FI; Harkness EF; Evans DGR
    Eur J Hum Genet; 2020 Nov; 28(11):1541-1547. PubMed ID: 32651552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.
    Manchanda R; Sun L; Sobocan M; Rodriguez IV; Wei X; Kalra A; Oxley S; Sideris M; Fierheller CT; Morgan RD; Chandrasekaran D; Rust K; Spiliopoulou P; Miller RE; Crusz SM; Lockley M; Singh N; Faruqi A; Casey L; Brockbank E; Phadnis S; Mills-Baldock T; El-Khouly F; Jenkins LA; Wallace A; Ahmed M; Kumar A; Swisher EM; Gourley C; Norquist BM; Evans DG; Legood R
    J Natl Compr Canc Netw; 2024 Apr; 22(2D):. PubMed ID: 38866043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of germline pathogenic
    Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
    J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting the likelihood of a
    Morgan RD; Burghel GJ; Flaum N; Bulman M; Smith P; Clamp AR; Hasan J; Mitchell C; Salih Z; Woodward ER; Lalloo F; Shaw J; Desai S; Crosbie EJ; Edmondson RJ; Schlecht H; Wallace AJ; Jayson GC; Evans DGR
    J Clin Pathol; 2023 Oct; 76(10):684-689. PubMed ID: 35738887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uptake of testing for germline
    Stearnes G; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Cohen PA
    Int J Gynecol Cancer; 2019 Jul; 29(6):1038-1042. PubMed ID: 31101686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?
    Morgan RD; Burghel GJ; Flaum N; Bulman M; Smith P; Clamp AR; Hasan J; Mitchell CL; Salih Z; Woodward ER; Lalloo F; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
    Br J Cancer; 2022 Jul; 127(1):163-167. PubMed ID: 35260807
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Lanjouw L; Mourits MJE; Bart J; Ter Elst A; Berger LPV; van der Hout AH; Alam N; de Bock GH
    Int J Gynecol Cancer; 2023 Aug; 33(8):1260-1269. PubMed ID: 37137525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First?
    Witjes VM; Ligtenberg MJL; Vos JR; Braspenning JCC; Ausems MGEM; Mourits MJE; de Hullu JA; Adang EMM; Hoogerbrugge N
    Gynecol Oncol; 2023 Jul; 174():121-128. PubMed ID: 37182432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.
    Witjes VM; van Bommel MHD; Ligtenberg MJL; Vos JR; Mourits MJE; Ausems MGEM; de Hullu JA; Bosse T; Hoogerbrugge N
    Gynecol Oncol; 2022 Jan; 164(1):221-230. PubMed ID: 34702566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
    Eccleston A; Bentley A; Dyer M; Strydom A; Vereecken W; George A; Rahman N
    Value Health; 2017 Apr; 20(4):567-576. PubMed ID: 28407998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
    Jorge S; McFaddin AS; Doll KM; Pennington KP; Norquist BM; Bennett RL; Pritchard CC; Swisher EM
    Gynecol Oncol; 2020 Mar; 156(3):517-522. PubMed ID: 31883735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real-life experience.
    Rust K; Spiliopoulou P; Tang CY; Bell C; Stirling D; Phang T; Davidson R; Mackean M; Nussey F; Glasspool RM; Reed NS; Sadozye A; Porteous M; McGoldrick T; Ferguson M; Miedzybrodzka Z; McNeish IA; Gourley C
    BJOG; 2018 Oct; 125(11):1451-1458. PubMed ID: 29460478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low BRCA1 and BRCA2 Germline Mutation Rates in a French-Canadian Population with a Diagnosis of Epithelial Tubo-Ovarian Carcinoma.
    Bernard J; Mehros W; Gregoire J; Douville P; Renaud MC; Sebastianelli A; Langlais EL; Plante M
    J Obstet Gynaecol Can; 2022 Oct; 44(10):1047-1053. PubMed ID: 35779836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline and somatic testing for ovarian Cancer: An SGO clinical practice statement.
    Gressel GM; Frey MK; Norquist B; Senter L; Blank SV; Urban RR
    Gynecol Oncol; 2024 Feb; 181():170-178. PubMed ID: 38215513
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Talwar V; Rauthan A
    Indian J Cancer; 2022 Mar; 59(Supplement):S56-S67. PubMed ID: 35343191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
    Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
    J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.
    Gori S; Barberis M; Bella MA; Buttitta F; Capoluongo E; Carrera P; Colombo N; Cortesi L; Genuardi M; Gion M; Guarneri V; Incorvaia L; La Verde N; Lorusso D; Marchetti A; Marchetti P; Normanno N; Pasini B; Pensabene M; Pignata S; Radice P; Ricevuto E; Sapino A; Tagliaferri P; Tassone P; Trevisiol C; Truini M; Varesco L; Russo A;
    Crit Rev Oncol Hematol; 2019 Aug; 140():67-72. PubMed ID: 31176273
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Piedimonte S; Power J; Foulkes WD; Weber E; Palma L; Schiavi A; Ambrosio E; Konci R; Gilbert L; Jardon K; Baret L; Zeng X
    Int J Gynecol Cancer; 2020 Nov; 30(11):1757-1761. PubMed ID: 32759180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1/2 germline testing in non-mucinous epithelial ovarian carcinoma: changing international practice and implications for service provision.
    Coakley M; Cleary V; Power N; O'Reilly S
    Eur J Hum Genet; 2017 Feb; 25(2):167-168. PubMed ID: 27759028
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.